A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
NCT06810934
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to test two investigational COVID-19 booster vaccines, called CoTend-s3BXBB and CoTend-BXBB, in healthy volunteers ages 40-64. The CoTend-s3BXBB vaccine includes a component called "s3", which was designed to improve the body's response to the vaccine. CoTend-BXBB is the same vaccine without s3. The main questions the study aims to answer are: 1) Is the investigational vaccine safe? 2) Does "s3" lead to bigger, broader, and longer-lasting responses to the vaccine? 5 different doses of the vaccines will be studied.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- COVID-19
- SARS-CoV-2 Infection
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 40 to 64 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Kara Chew
- Last updated on ClinicalTrials.gov
- August 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- UCLA Westwood · Los Angeles, CA
- UCSF Community and Clinical Research Center · San Francisco, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.